Johnson & Johnson's LifeScan gets FDA warning for QS violations

LifeScan is once again in trouble with the US FDA. The company received an FDA warning letter on December 7 for quality systems violations identified during an April 6-June 30 inspection of its plant in Milpitas, California, where the One Touch Ultra blood glucose monitor is manufactured.

LifeScan is once again in trouble with the US FDA. The company received an FDA warning letter on December 7 for quality systems violations identified during an April 6-June 30 inspection of its plant in Milpitas, California, where the One Touch Ultra blood glucose monitor is manufactured.

Among the issues cited in the warning letter was a failure to investigate several consumer complaints about the monitor being...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Medtech Insight

Remote Regulatory Assessments Become Swiss Army Knife For US FDA’s Oversight Of Facilities

 

“RRAs are valuable oversight tools and under certain circumstances, can assist FDA in its mission to protect public health, oversee regulated industry, and help ensure regulated products comply with FDA requirements,” according to final guidance.

FDA Greenlights Expanded Use Of Boston Scientific’s Pulse Field Ablation System

 

A recent approval from the US FDA allowing Boston Scientific to broaden its labeling for its pulse field ablation system means more patients with one type of AFib will have access to a promising new treatment.

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By 

Joshi joins the parent company of Citeline, home of Medtech Insight, to focus on AI, business harmonization and long-term growth.